The Discounted Cash Flow (DCF) valuation of Protagonist Therapeutics Inc (PTGX) is (97.85) USD. With the latest stock price at 99.56 USD, the upside of Protagonist Therapeutics Inc based on DCF is -198.3%.
Based on the latest price of 99.56 USD and our DCF valuation, Protagonist Therapeutics Inc (PTGX) is a sell. selling PTGX stocks now will result in a potential gain of 198.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.4% - 6.4% | 5.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (442.12) - (55.82) | (97.85) |
| Upside | -544.1% - -156.1% | -198.3% |